Literature DB >> 16603516

Intradermal immune response after infection with Vaccinia virus.

Nathalie Jacobs1, Ron A-J Chen, Caroline Gubser, Pilar Najarro, Geoffrey L Smith.   

Abstract

Although Vaccinia virus (VACV) was used to eradicate smallpox by dermal vaccination, there is little information available about the immune response induced at the vaccination site. Previously, an intradermal murine model that mimics smallpox vaccination was established. Here, this model was used to investigate which leukocytes are recruited to the infected lesion and what are the kinetics of recruitment. Data presented show that VACV infection induced the infiltration of macrophages, followed by granulocytes and lymphocytes. Up to 4 days post-infection, the major lymphocyte population was TCRgammadelta T cells, but thereafter, there was a large recruitment of CD4(+) and CD8(+) T cells. Interestingly, the majority of T cells expressed the natural killer-cell marker DX5. This report is the first to characterize the local immune response sequence to VACV infection and represents a benchmark against which the responses induced by genetically modified VACVs may be compared.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16603516     DOI: 10.1099/vir.0.81556-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  20 in total

1.  Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides.

Authors:  Zhenping Wang; Yuping Lai; Jamie J Bernard; Daniel T Macleod; Anna L Cogen; Bernard Moss; Anna Di Nardo
Journal:  J Immunol       Date:  2011-12-02       Impact factor: 5.422

Review 2.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  Role for CCR5 in dissemination of vaccinia virus in vivo.

Authors:  Ramtin Rahbar; Thomas T Murooka; Eleanor N Fish
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

4.  Deletion of the K1L Gene Results in a Vaccinia Virus That Is Less Pathogenic Due to Muted Innate Immune Responses, yet Still Elicits Protective Immunity.

Authors:  Ariana G Bravo Cruz; Aiguo Han; Edward J Roy; Arielle B Guzmán; Rita J Miller; Elizabeth A Driskell; William D O'Brien; Joanna L Shisler
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

5.  The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice.

Authors:  Salvador Iborra; Helena M Izquierdo; María Martínez-López; Noelia Blanco-Menéndez; Caetano Reis e Sousa; David Sancho
Journal:  J Clin Invest       Date:  2012-04-16       Impact factor: 14.808

6.  The Vaccinia virus complement control protein modulates adaptive immune responses during infection.

Authors:  Natasha M Girgis; Brian C Dehaven; Yuhong Xiao; Edward Alexander; Kendra M Viner; Stuart N Isaacs
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

7.  Kinetics of immune cell infiltration in vaccinia virus keratitis.

Authors:  Sharon Altmann; Megan Toomey; Brittany Nesbit; Kim McIntyre; Jill Covert; Richard Redd Dubielzig; Gary Leatherberry; Elizabeth Adkins; Christopher J Murphy; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-07       Impact factor: 4.799

Review 8.  The immunologic aspects of poxvirus oncolytic therapy.

Authors:  Andrea Worschech; D Haddad; D F Stroncek; E Wang; Francesco M Marincola; Aladar A Szalay
Journal:  Cancer Immunol Immunother       Date:  2009-03-06       Impact factor: 6.968

9.  Vaccinia virus lacking the Bcl-2-like protein N1 induces a stronger natural killer cell response to infection.

Authors:  Nathalie Jacobs; Nathan W Bartlett; Richard H Clark; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2008-11       Impact factor: 3.891

10.  Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence.

Authors:  Aodhnait S Fahy; Richard H Clark; Emily F Glyde; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2008-10       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.